Sinovac Biotech Ltd (SVA) 5.82 $SVA
Simavita Secures $7.3m in Funding
Marketwire Canada - Wed Jun 29, 10:45AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 29, 2016) - Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE:SV)(ASX:SVA) is pleased to announce that as a result of significant support from its shareholders it had raised $7,353,000.
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Limited: 2016 Special General Meeting Results
Marketwire Canada - Thu Jun 23, 1:20PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2016) - Simavita Limited ("Simavita" or the "Company" (TSX VENTURE:SV)(ASX:SVA) is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 10:00 am today (Australian Eastern Standard Time) in Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are attached.
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Global Rubella Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sinovac Biotech, Biological E, Prometheon Pharma - Research and Markets
BusinessWire - Thu Jun 09, 9:01AM CDT
Research and Markets has announced the addition of the "Rubella - Pipeline Review, H1 2016" report to their offering.
SVA: 5.82 (+0.03)
Sinovac Reports Unaudited First Quarter 2016 Financial Results
PR Newswire - Thu May 26, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter ended March 31, 2016.
SVA: 5.82 (+0.03)
Sinovac to Host Conference Call to Report First Quarter of 2016 Unaudited Financial Results
PR Newswire - Fri May 20, 5:03AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter, ended March 31, 2016, after the market closes on Thursday, May 26, 2016. The Company will host a conference call on Friday, May 27, 2016, at 8:00 a.m. EDT (Friday, May 27, 2016 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.82 (+0.03)
Simavita Announces Change to the Board
Marketwire Canada - Fri May 06, 9:59AM CDT
SYDNEY, AUSTRALIA--(Marketwired - May 6, 2016) - Simavita Limited ("Simavita" or the "Company" (TSX VENTURE:SV)(ASX:SVA) today announced that, as foreshadowed in the changes to board and management announced on April 27, 2016, Craig Holland, Non-Executive Director and Chairman of the Audit & Risk Committee has resigned from the Board of Directors effective immediately.
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Announces Changes to the Board and Management; Strong Support from Existing Shareholders for the Company; Additional Financing / Issue of Notes
Marketwired - Wed Apr 27, 7:02AM CDT
Simavita Limited ("Simavita" or the "Company" (TSX VENTURE: SV)(ASX: SVA) today announced that the Company, supported by its major shareholders, has completed a review of its Board, operations; executive management and working capital.
RMD: 64.51 (+1.16), SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Sinovac Files 2015 Annual Report on Form 20-F
PR Newswire - Tue Apr 26, 3:12AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2015 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2015 on April 25, 2016. The Annual Report on Form 20-F is now available on the Company's website under SEC Filings in the Investor Relations section.
SVA: 5.82 (+0.03)
Sinovac Special Committee Engages Financial and Legal Advisors
PR Newswire - Thu Apr 14, 5:00AM CDT
Sinovac Biotech Ltd. ("Sinovac" or the "Company" (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the independent special committee of the Company's Board of Directors, formed to consider "going private" proposals received by the Company, has appointed yesterday Duff & Phelps (Duff & Phelps, LLC and Duff & Phelps Securities, LLC) as its financial advisor to assist it in this process. The special committee has also appointed Weil, Gotshal & Manges as its U.S. legal counsel, and Leslie-Ann Brissett Legal Services as its Antigua counsel. Latham & Watkins is serving as U.S. legal counsel, and Delaney Law is serving as Antigua legal counsel, to the Company.
SVA: 5.82 (+0.03)
Sinovac posts 4Q profit
Automated Insights - Tue Apr 05, 5:37AM CDT
BEIJING (AP) _ Sinovac Biotech Ltd. (SVA) on Tuesday reported fourth-quarter net income of $504,000.
SVA: 5.82 (+0.03)
Sinovac Reports Unaudited Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Apr 05, 5:16AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and twelve month financial results for the period ended December 31, 2015.
SVA: 5.82 (+0.03)
Simavita to Integrate SIM(TM) With Leading North American Electronic Health Record Provider PointClickCare
Marketwire Canada - Mon Apr 04, 10:57AM CDT
Highlights
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2015 Unaudited Financial Results
PR Newswire - Tue Mar 29, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2015, before market opens on Tuesday, April 5, 2016. The Company will host a conference call on Tuesday, April 5, 2016, at 8:00 a.m. EDT (Tuesday, April 5, 2015 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.82 (+0.03)
Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights
PR Newswire - Mon Mar 28, 5:00PM CDT
Sinovac Biotech Ltd. ("Sinovac" or the "Company" (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has adopted a shareholder rights plan (the "Rights Plan", pursuant to which the board of directors declared a dividend distribution of one preferred share purchase right on each outstanding common share of the Company.
SVA: 5.82 (+0.03)
Shares of SVA Up 12.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 07, 4:20PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on February 1st, 2016 at $5.69. In approximately 1 month, Sinovac Biotech has returned 12.51% as of today's recent price of $6.40.
SVA: 5.82 (+0.03)
Simavita Limited: Issue of Placement Securities
Marketwired - Wed Mar 02, 4:07PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" advises that following the Company's shareholder meeting on February 26, 2016 and approval of Resolution 3, it has allotted a total of 6,666,667 shares (represented by 6,666,667 CHESS Depository Interests ("CDIs") and 1,333,333 unlisted options (the "Placement Options" which are issued on the basis of one attaching Placement Option for every five shares issued pursuant to the placement. Each Placement Option will entitle the holder to acquire one share/CDI in the Company at an exercise price of AUD$0.15 on or before 2 March 2017 to Dussman Pty Ltd. The issue of the CDIs at an issue price of AUD$0.15 per CDI raised $1,000,000.
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Limited: Release of Restricted Securities
Marketwired - Fri Feb 05, 12:57PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" announces the release of restricted securities from ASX escrow (Restricted Securities).
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Secures $7.3m in Funding
Marketwire Canada - Wed Jun 29, 10:45AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 29, 2016) - Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE:SV)(ASX:SVA) is pleased to announce that as a result of significant support from its shareholders it had raised $7,353,000. SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Limited: 2016 Special General Meeting Results
Marketwire Canada - Thu Jun 23, 1:20PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2016) - Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE:SV)(ASX:SVA) is pleased to announce the results of the Special Meeting of the Company's shareholders which was held at 10:00 am today (Australian Eastern Standard Time) in Sydney, Australia. All nine resolutions that were put before the meeting were passed on a show of hands. Details of the proxy votes received by the Company in relation to each resolution in the notice of special meeting and information circular are attached. SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Global Rubella Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sinovac Biotech, Biological E, Prometheon Pharma - Research and Markets
BusinessWire - Thu Jun 09, 9:01AM CDT
Research and Markets has announced the addition of the "Rubella - Pipeline Review, H1 2016" report to their offering.
SVA: 5.82 (+0.03)
Sinovac Reports Unaudited First Quarter 2016 Financial Results
PR Newswire - Thu May 26, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter ended March 31, 2016.
SVA: 5.82 (+0.03)
Sinovac to Host Conference Call to Report First Quarter of 2016 Unaudited Financial Results
PR Newswire - Fri May 20, 5:03AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter, ended March 31, 2016, after the market closes on Thursday, May 26, 2016. The Company will host a conference call on Friday, May 27, 2016, at 8:00 a.m. EDT (Friday, May 27, 2016 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.82 (+0.03)
Simavita Announces Change to the Board
Marketwire Canada - Fri May 06, 9:59AM CDT
SYDNEY, AUSTRALIA--(Marketwired - May 6, 2016) - Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE:SV)(ASX:SVA) today announced that, as foreshadowed in the changes to board and management announced on April 27, 2016, Craig Holland, Non-Executive Director and Chairman of the Audit & Risk Committee has resigned from the Board of Directors effective immediately. SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Announces Changes to the Board and Management; Strong Support from Existing Shareholders for the Company; Additional Financing / Issue of Notes
Marketwired - Wed Apr 27, 7:02AM CDT
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV)(ASX: SVA) today announced that the Company, supported by its major shareholders, has completed a review of its Board, operations; executive management and working capital. RMD: 64.51 (+1.16), SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Sinovac Files 2015 Annual Report on Form 20-F
PR Newswire - Tue Apr 26, 3:12AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2015 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2015 on April 25, 2016. The Annual Report on Form 20-F is now available on the Company's website under SEC Filings in the Investor Relations section.
SVA: 5.82 (+0.03)
Sinovac Special Committee Engages Financial and Legal Advisors
PR Newswire - Thu Apr 14, 5:00AM CDT
Sinovac Biotech Ltd. ("Sinovac" or the "Company"
(NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the independent special committee of the Company's Board of Directors, formed to consider "going private" proposals received by the Company, has appointed yesterday Duff & Phelps (Duff & Phelps, LLC and Duff & Phelps Securities, LLC) as its financial advisor to assist it in this process. The special committee has also appointed Weil, Gotshal & Manges as its U.S. legal counsel, and Leslie-Ann Brissett Legal Services as its Antigua counsel. Latham & Watkins is serving as U.S. legal counsel, and Delaney Law is serving as Antigua legal counsel, to the Company. SVA: 5.82 (+0.03)
Sinovac posts 4Q profit
Automated Insights - Tue Apr 05, 5:37AM CDT
BEIJING (AP) _ Sinovac Biotech Ltd. (SVA) on Tuesday reported fourth-quarter net income of $504,000.
SVA: 5.82 (+0.03)
Sinovac Reports Unaudited Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Tue Apr 05, 5:16AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and twelve month financial results for the period ended December 31, 2015.
SVA: 5.82 (+0.03)
Simavita to Integrate SIM(TM) With Leading North American Electronic Health Record Provider PointClickCare
Marketwire Canada - Mon Apr 04, 10:57AM CDT
Highlights
SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2015 Unaudited Financial Results
PR Newswire - Tue Mar 29, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2015, before market opens on Tuesday, April 5, 2016. The Company will host a conference call on Tuesday, April 5, 2016, at 8:00 a.m. EDT (Tuesday, April 5, 2015 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
SVA: 5.82 (+0.03)
Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights
PR Newswire - Mon Mar 28, 5:00PM CDT
Sinovac Biotech Ltd. ("Sinovac" or the "Company"
(NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has adopted a shareholder rights plan (the "Rights Plan", pursuant to which the board of directors declared a dividend distribution of one preferred share purchase right on each outstanding common share of the Company. SVA: 5.82 (+0.03)
Shares of SVA Up 12.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 07, 4:20PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on February 1st, 2016 at $5.69. In approximately 1 month, Sinovac Biotech has returned 12.51% as of today's recent price of $6.40.
SVA: 5.82 (+0.03)
Simavita Limited: Issue of Placement Securities
Marketwired - Wed Mar 02, 4:07PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
advises that following the Company's shareholder meeting on February 26, 2016 and approval of Resolution 3, it has allotted a total of 6,666,667 shares (represented by 6,666,667 CHESS Depository Interests ("CDIs") and 1,333,333 unlisted options (the "Placement Options" which are issued on the basis of one attaching Placement Option for every five shares issued pursuant to the placement. Each Placement Option will entitle the holder to acquire one share/CDI in the Company at an exercise price of AUD$0.15 on or before 2 March 2017 to Dussman Pty Ltd. The issue of the CDIs at an issue price of AUD$0.15 per CDI raised $1,000,000. SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
Simavita Limited: Release of Restricted Securities
Marketwired - Fri Feb 05, 12:57PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
announces the release of restricted securities from ASX escrow (Restricted Securities). SV.VN: 0.035 (unch), SVA: 5.82 (+0.03)
